Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer - Full Text View

Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer

This study is ongoing, but not recruiting participants.

Sponsored by:	National Center for Research Resources (NCRR)
Information provided by:	National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:	NCT00006198

Purpose

This is a clinical trial to test the safety and efficacy of the drug thalidomide in combination with a procedure called chemoembolization in patients with inoperable liver cancer. Chemoembolization is the process by which chemotherapy is instilled directly into the blood vessels feeding the tumor, so that the blood vessels feeding the tumor may be blocked. Chemoembolization consists of two separate procedures. It will be done by infusing chemotherapy with the drug doxorubicin through the hepatic artery into the liver and then by infusing collagen to cut off the blood supply to the tumor. A catheter will be inserted at various times to allow for these infusions.

The objectives are to investigate the feasibility and potential activity of chronic administration of thalidomide in patients with unresectable hepatocellular cancer who receive chemoembolization to predominant tumor masses. The toxicity of thalidomide in these patients will be evaluated. Overall safety will also be assessed. Serum levels of angiogenic cytokines such as VEGF, bFGF, and TNF-a, that are believed to have a role in hepatocellular carcinoma, will be collected.

Condition	Intervention	Phase
Liver Cancer	Drug: thalidomide Procedure: chemoembolization with doxorubicin/collagen	Phase II

MedlinePlus related topics:

Cancer Liver Cancer

Drug Information available for:

Doxorubicin Doxorubicin hydrochloride Thalidomide

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with unresectable hepatocellular carcinoma.
MRI of liver must show discrete tumor nodules. Lesions on angiography must be hypervascular.
Patient must have the following minimum labs: ANC> 1200/mm3; Hemoglobin > 8 mg/dl; platelets > 50,000 mm3; hepatic transaminases < 5x normal; bilirubin < 3.0 mg/dl; and creatinine < 1.5 mg/dl.
ECOG performance status > 2.
No history of prior chemotherapy or biologic therapy for hepatocellular carcinoma.
No other history of malignancy other than curatively resected basal cell carcinoma of the skin or carcinoma in situ of the cervix.
Patients must not be pregnant or lactating.
Sexually active men and women of childbearing age must use adequate contraception. All patients must understand the potential for severe birth defects with thalidomide and must be able to follow instructions to avoid conception while taking thalidomide

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006198

Locations


United States, New York
	Kaplan Comprehensive Cancer Center
	New York, New York, United States, 10016

Sponsors and Collaborators

National Center for Research Resources (NCRR)

More Information

Study ID Numbers:	NCRR-M01RR00096-0958, M01RR00096
First Received:	September 9, 2000
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00006198
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Liver Neoplasms

Liver Diseases

Digestive System Diseases

Digestive System Neoplasms

Thalidomide

Liver neoplasms

Gastrointestinal Neoplasms

Doxorubicin

Hepatocellular carcinoma

Additional relevant MeSH terms:

Anti-Infective Agents

Immunologic Factors

Antineoplastic Agents

Growth Substances

Physiological Effects of Drugs

Immunosuppressive Agents

Angiogenesis Inhibitors

Pharmacologic Actions

Anti-Bacterial Agents

Neoplasms

Neoplasms by Site

Therapeutic Uses

Growth Inhibitors

Angiogenesis Modulating Agents

Leprostatic Agents

ClinicalTrials.gov processed this record on November 20, 2008